Drug intelligence / Profile preview

AD-2101 + AD-2102

Development stage: Phase 1
Lead developer: Addpharma
Modality: Small Molecules
Administration: Oral (inferred From Standard Practice For Small Molecules In Hypertension Trials; Not Explicitly Stated)

Overview

AD-2101 + AD-2102 is an investigational combination of two small molecule drugs developed by Addpharma for the treatment of hypertension and potentially other cardiovascular diseases. The combination has been studied in a Phase 1 randomized, open-label, multiple-dose crossover clinical trial to evaluate pharmacokinetic interactions, safety, and tolerability compared to administration of each agent alone. The primary focus was on healthy male subjects. Detailed mechanisms of action and molecular targets for either component have not been disclosed in public sources as of June 2025[1][3].

Beyond the preview

Go deeper on AD-2101 + AD-2102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AD-2101 + AD-2102.